Pharmaceuticals, Biotechnology and Life Sciences
Virpax Pharmaceuticals has successfully completed a pre-Investigational New Drug (IND) Application meeting with the U.S. Food and Drug Administration (FDA)…
As the corona virus pandemic makes the conduct of clinical studies very complex and leads to standstill in many places,…
Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx, said that the company will release topline data from the LUMINA-2 study of CCX140.
Covid-19 has caused great interruption to pharmaceutical trials, as most resources have shifted to finding a vaccine and many ongoing trials have been disrupted, according to a report by Wakefield Research, an independent provider of market research and market intelligence.
Leinco Technologies and Vanderbilt University Medical Center (VUMC) have agreed to scale up production of its most promising antibodies for development of a rapid, point of care COVID-19 diagnostic test.
Alvotech has named Tanya Zharov as deputy chief executive officer in Iceland to oversee Icelandic operations and administration, including the Reykjavik site leadership team, human resources, business operations, shared services and facilities.
Companies selling personal protective equipment like face masks and gloves seem to be having a hard time getting their products to their target audience, no thanks to the practices of online platforms such as search engines, online stores, and social media networking sites.
Abivax said Thursday that ABX464 inhibits replication of SARS-CoV-2 in an in vitro reconstituted human respiratory epithelium model, as assessed by Transepithelial electrical resistance and RTqPCR.
“When Sarclisa was added to standard-of-care treatment carfilzomib and dexamethasone in this phase 3 trial, results clearly demonstrated a significant reduction in risk of disease progression or death, ” said John Reed, M.D., Ph.D., Global Head of Research and Development at Sanofi.
Neurocrine Biosciences has exercised its option to license the global rights to Idorsia’s ACT-709478, as it plans to initiate a Phase 2 study with this potent, selective, orally-active and brain penetrating T-type calcium channel blocker for the treatment of a rare pediatric epilepsy in the second half of 2020.